GlassScriptPhysician profile
Islam Badawy
NPI 1922425453
$11,006.99
in general payments reported to CMS, 2019-2025
39 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $261 · 2021: $1,315 · 2022: $3,495 · 2023: $1,297 · 2024: $2,742 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,056 · Travel and Lodging: $1,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,056.37 |
| Travel and Lodging | $1,269.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,188.21 | 2021-2025 | Abre, Symplicity G3, In.Pact Admiral |
| Philips North America LLC | $1,648.81 | 2024-2025 | (Bq9) Coronary Ivus, (6346) Intrasight Mobile, Coronary Other |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $948.72 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $838.46 | 2019-2025 | Watchman Flx, Rhythmia Mapping System, Ekosonic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $597.49 | 2019-2023 | Jardiance |
| Abiomed | $591.86 | 2022-2025 | Impella |
| Janssen Pharmaceuticals, INC | $420.25 | 2020-2023 | Xarelto |
| Abbott Laboratories | $365.27 | 2020-2024 | Diamondback Peripheral, Perclose Prostyle, Cardiomems |
| Novartis Pharmaceuticals Corporation | $362.20 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $320.86 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $310.37 | 2021-2023 | Verquvo |
| Cardiovascular Systems INC. | $290.62 | 2021-2022 | |
| Esperion Therapeutics, INC. | $206.59 | 2021-2023 | Nexletol |
| Penumbra, INC. | $199.90 | 2024-2025 | Indigo System |
| Chiesi USA, INC. | $197.00 | 2021-2023 | Cleviprex, Kengreal |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $174.15 | 2021-2023 | Onpattro |
| Pfizer INC. | $163.92 | 2021-2023 | |
| Kestra Medical Technology Services, INC. | $140.47 | 2022-2023 | Assure Wcd |
| Shockwave Medical, INC | $138.21 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $118.26 | 2019-2023 | Repatha |
| Stryker Corporation | $101.80 | 2025 | Artix Mt |
| E.R. Squibb & Sons, L.L.C. | $99.84 | 2025 | Camzyos |
| Inari Medical, INC. | $95.80 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| W. L. Gore & Associates, INC. | $94.77 | 2022-2025 | Gore Viabahn Vbx Balloon Expandable Endo |
| Edwards Lifesciences Corporation | $65.84 | 2020-2025 | Pascal |
| Itamar Medical INC | $45.19 | 2023 | Watchpatone |
| Kiniksa Pharmaceuticals, LTD. | $39.65 | 2021 | |
| Amarin Pharma, INC. | $30.16 | 2021-2022 | |
| Avinger INC. | $24.71 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $24.03 | 2022 | |
| Vifor Pharma, INC. | $23.68 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.34 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.24 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $18.70 | 2023 | Inpefa |
| Teleflex LLC | $17.30 | 2024 | Guideliner |
| Ekos Corporation | $16.38 | 2019 | |
| Terumo Medical Corporation | $14.34 | 2021 | |
| Cordis US Corp. | $13.98 | 2025 | |
| Hikma Pharmaceuticals USA | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Islam Badawy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.